These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 15161808)

  • 1. Lipids and lipoproteins in patients with type 2 diabetes.
    Krauss RM
    Diabetes Care; 2004 Jun; 27(6):1496-504. PubMed ID: 15161808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetic dyslipidemia and atherosclerosis.
    Shepherd J
    Schweiz Med Wochenschr; 1994 Nov; 124(44):1933-7. PubMed ID: 7973520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
    Oki JC
    Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis.
    Ginsberg HN
    Diabetes Care; 1991 Sep; 14(9):839-55. PubMed ID: 1959476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein particles and incident type 2 diabetes in the multi-ethnic study of atherosclerosis.
    Mackey RH; Mora S; Bertoni AG; Wassel CL; Carnethon MR; Sibley CT; Goff DC
    Diabetes Care; 2015 Apr; 38(4):628-36. PubMed ID: 25592196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes.
    Vergès B
    Diabetes Metab; 2005 Nov; 31(5):429-39. PubMed ID: 16357786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis.
    Vergès BL
    Diabetes Metab; 1999 Jun; 25 Suppl 3():32-40. PubMed ID: 10421991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial.
    Dugani SB; Akinkuolie AO; Paynter N; Glynn RJ; Ridker PM; Mora S
    JAMA Cardiol; 2016 May; 1(2):136-45. PubMed ID: 27347563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes and plasma lipoproteins in Native Americans. Studies of the Pima Indians.
    Howard BV
    Diabetes Care; 1993 Jan; 16(1):284-91. PubMed ID: 8422793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyslipoproteinaemia in manifest diabetes.
    Manzato E; Crepaldi G
    J Intern Med Suppl; 1994; 736():27-31. PubMed ID: 7986305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies.
    Hayashi T; Hirano T; Yamamoto T; Ito Y; Adachi M
    Metabolism; 2006 Jul; 55(7):879-84. PubMed ID: 16784958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding and treating dyslipidemia associated with noninsulin-dependent diabetes mellitus and hypertension.
    McKenney JM
    Pharmacotherapy; 1993; 13(4):340-52. PubMed ID: 8361860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study.
    Festa A; Williams K; Hanley AJ; Otvos JD; Goff DC; Wagenknecht LE; Haffner SM
    Circulation; 2005 Jun; 111(25):3465-72. PubMed ID: 15983261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.
    Chapman MJ; Guérin M; Bruckert E
    Eur Heart J; 1998 Feb; 19 Suppl A():A24-30. PubMed ID: 9519339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of hypercholesterolaemia in the patient with diabetes.
    Packard C; Olsson AG
    Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.
    Bays H; Giezek H; McKenney JM; O'Neill EA; Tershakovec AM
    Metab Syndr Relat Disord; 2012 Aug; 10(4):260-6. PubMed ID: 22400810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiology of diabetic dyslipidaemia: where are we?
    Vergès B
    Diabetologia; 2015 May; 58(5):886-99. PubMed ID: 25725623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.